Skip to main content

narsoplimab

Generic: Narsoplimab·Code: OMS721

narsoplimab: 4 clinical trials tracked.

narsoplimab evidence translation

What we can confirm

4 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about narsoplimab, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trial Registry Records (4)

Single Patient Expanded Access Treatment Plan (EAP; Also Known As A Compassionate Use Plan) To Provide Patients Access To The Investigational Product Narsoplimab

NCT04247906Registry updated 2026-03-05·OMER
Approved for marketing
Expanded AccessOmeros Corporation

A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Adolescents

NCT03205995Registry updated 2025-12-10·Phase 3·OMER
Terminated

Primary endpoint: Platelet Count (10^9 Platelets/L) Change From Baseline at Week 26

Interventionalopen6 targetStarted 2018-05Completion 2021-024 sites · Lithuania, Poland, Taiwan, United StatesOmeros Corporation

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)

NCT03608033Registry updated 2025-12-09·Phase 3·OMER
Terminated

Primary endpoint: Percent Change in 24-hour UPE in g/Day Compared to Baseline

InterventionalRandomizedquadruple360 targetStarted 2018-04Completion 2024-0150 sites · Argentina, Australia, Belgium, Bulgaria…Omeros Corporation

A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease

NCT02682407Registry updated 2026-03-30·Phase 2·OMER
Terminated

Primary endpoint: Cohort 1-3: Proportion of IgAN, LN, MN, C3 Glomerulopathy Participants With Treatment Related Adverse Events (AE).

InterventionalRandomizedtriple31 targetStarted 2016-03Completion 2020-0812 sites · Hong Kong, United StatesOmeros Corporation